Pharming Group N.V. Files 6-K with October Press Release
Ticker: PHAR · Form: 6-K · Filed: Oct 22, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-form-6k, press-release
TL;DR
Pharming Group N.V. (PHAR) filed a 6-K on 10/22/25, including a press release from 10/20/25. Standard update.
AI Summary
Pharming Group N.V. filed a Form 6-K on October 22, 2025, furnishing a press release dated October 20, 2025. The filing is related to the month of October 2025 and is submitted under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The company's principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Why It Matters
This filing provides an update from Pharming Group N.V. to the SEC, indicating ongoing corporate communications and regulatory compliance for the period ending October 2025.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 001-39822 — SEC File Number (Identifies the specific SEC filing for Pharming Group N.V.)
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- 001-39822 (dollar_amount) — SEC File Number
- 20251020 (date) — Press Release Date
- 20251022 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information that Pharming Group N.V. has made or will make public, is required to or has agreed to file with the SEC, and is not otherwise required to file on the Form 20-F.
What specific document is furnished as Exhibit 99.1?
Exhibit 99.1 is a press release of Pharming Group N.V. dated October 20, 2025.
When was Pharming Group N.V. incorporated or organized?
The filing does not explicitly state the incorporation date, but it indicates the State of Incorporation is P7 and the Fiscal Year End is 1231.
What is the business address of Pharming Group N.V.?
The business address is Darwinweg 24, 2333 CR Leiden, The Netherlands.
Under which rules is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 2,423 words · 10 min read · ~8 pages · Grade level 12.7 · Accepted 2025-10-22 09:36:58
Filing Documents
- pharminggroupannouncespres.htm (6-K) — 65KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-25-000047.txt ( ) — 233KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to